Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Zinner

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Clinical Lung Cancer|September 15, 2010
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histologyRalph G Zinner, Scott B Saxman, Guangbin Peng, et al.
Zeitschrift Fur Erkrankungen Der Atmungsorgane|January 1, 1985
[Thallium myocardial scintigraphy, hemodynamics and left ventricular wall kinetics in patients with suspected myocardial sarcoidosis]H Schaedel, D Kirsten, D Gottschild, et al.
Progress in Clinical and Biological Research|January 1, 1990
A newly developed LDL-binding materialE Behm, F Loth, D Toewe, et al.
Clinical Lung Cancer|October 30, 2018
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D Patel, Luis Paz-Ares, Ralph G Zinner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag, David J Stewart, Frank V Fossella, et al.
Biomedizinische Technik. Biomedical Engineering|December 22, 1998
[In vitro studies of hemocompatibility of surface modified fluoropolymers]G Zinner, C Werner, D Behrend, et al.
Investigational New Drugs|April 24, 2013
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumorsAung Naing, Siqing Fu, Ralph G Zinner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancerWilliam N William, Ralph G Zinner, Daniel D Karp, et al.
Molecular Carcinogenesis|July 29, 2003
Prostate-specific antitumor activity by probasin promoter-directed p202 expressionYong Wen, Dipak Giri, Duen-Hwa Yan, et al.
Current Medical Research and Opinion|March 10, 2017
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studiesIsamu Okamoto, Wolfgang H W Schuette, Thomas E Stinchcombe, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Clinical Lung Cancer|September 15, 2010
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histologyRalph G Zinner, Scott B Saxman, Guangbin Peng, et al.
Zeitschrift Fur Erkrankungen Der Atmungsorgane|January 1, 1985
[Thallium myocardial scintigraphy, hemodynamics and left ventricular wall kinetics in patients with suspected myocardial sarcoidosis]H Schaedel, D Kirsten, D Gottschild, et al.
Progress in Clinical and Biological Research|January 1, 1990
A newly developed LDL-binding materialE Behm, F Loth, D Toewe, et al.
Clinical Lung Cancer|October 30, 2018
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D Patel, Luis Paz-Ares, Ralph G Zinner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag, David J Stewart, Frank V Fossella, et al.
Biomedizinische Technik. Biomedical Engineering|December 22, 1998
[In vitro studies of hemocompatibility of surface modified fluoropolymers]G Zinner, C Werner, D Behrend, et al.
Investigational New Drugs|April 24, 2013
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumorsAung Naing, Siqing Fu, Ralph G Zinner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancerWilliam N William, Ralph G Zinner, Daniel D Karp, et al.
Molecular Carcinogenesis|July 29, 2003
Prostate-specific antitumor activity by probasin promoter-directed p202 expressionYong Wen, Dipak Giri, Duen-Hwa Yan, et al.
Current Medical Research and Opinion|March 10, 2017
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studiesIsamu Okamoto, Wolfgang H W Schuette, Thomas E Stinchcombe, et al.
Pageof 11